Showing 2491-2500 of 3039 results for "".
- BRIM Biotechnology Enters Trading in Taiwanhttps://modernod.com/news/brim-biotechnology-enters-otc-trading-in-taiwan/2480926/BRIM Biotechnology has entered OTC trading in Taiwan on June 23, 2022. Established in 2013, BRIM is a clinical-stage company developing novel regenerative therapies to help combat and cure ophthalmology and degenerative joint diseases. BRIM has several novel drug products
- Vision Expo West 2022 Opens Hotel Reservationshttps://modernod.com/news/vision-expo-west-2022-opens-hotel-reservations/2480917/The Vision Council and RX, co-organizers of Vision Expo, announced that reservations are now being accepted at Vision Expo West’s partner hotels for
- NIH Researchers Discover New Genetic Eye Diseasehttps://modernod.com/news/nih-researchers-discover-new-genetic-eye-disease/2480909/Researchers from the National Eye Institute (NEI) have identified a new disease that affects the macula. Scientists report their findings on the novel macular dystrophy, which is yet to be named, in JAMA Ophthalmology. Macular dystrophies are disorders that usually cause central visual l
- Eyenovia Announces Planned Chief Executive Officer Transitionhttps://modernod.com/news/eyenovia-announces-planned-chief-executive-officer-transition/2480898/Eyenovia announced that Sean Ianchulev, MD, co-founder, chief medical officer, and chief executive officer, will step down as chief executive officer and transition to the role of non-executive Chairman of the Board. The definitive timeline for the transition will be determin
- Alcon to Acquire Eysuvis and Inveltys from Kala Pharmaceuticalshttps://modernod.com/news/kala-pharmaceuticals-to-sell-eysuvis-and-inveltys-to-alcon/2480878/Alcon will significantly bolster its pharmaceutical offerings after reaching an agreement to acquire Kala Pharmaceuticals' commercial portfolio, which includes dry eye drug Eysuvis (loteprednol etabonate suspension 0.25%), and Inveltys (loteprednol etabonate
- New Study Highlights Patient Willingness to Adhere to Pre-Op Prephttps://modernod.com/news/new-study-highlights-patient-willingness-to-adhere-to-pre-op-prep/2480874/Bruder Healthcare announced new research that supports cataract surgeons and comanaging optometrists and ophthalmologists as they help patients prepare for surgery. This noninterventional, cross-sectional investigation of 278 US adults age 65 and older sought to identify cataract s
- Ocuphire Announces Positive Topline Results from LYNX-1 Phase 3 Trial Evaluating Nyxol Eye Drops for Night Vision Disturbanceshttps://modernod.com/news/ocuphire-announces-positive-topline-results-from-lynx-1-phase-3-trial-evaluating-nyxol-eye-drops-for-night-vision-disturbances/2480873/Ocuphire Pharma announced positive topline results from the LYNX-1 phase 3 pivotal clinical trial investigating its product candidate Nyxol for night (or dim light) vision disturbances (NVD). More than 650 subjects have now been exposed to Nyxol. NVD is a condition i
- Zeiss Offers New SLT Application for the Visulas Green Therapeutic Laserhttps://modernod.com/news/zeiss-offers-new-slt-application-for-the-visulas-green-therapeutic-laser/2480842/Zeiss Medical Technology announced that it now offers the new SLT add-on to its Visulas green laser, part of an integrated glaucoma workflow designed to advance safe and effective glaucoma treatment. The new SLT laser feature offers unique protocols that may im
- CooperVision Seeks Proposals for 2022 Science and Technology Awardshttps://modernod.com/news/coopervision-seeks-proposals-for-2022-science-and-technology-awards/2480832/To promote continuous advancement in contact lens research and development, CooperVision is now accepting submissions for its 2022 Science and Technology Awards program. The longstanding program fosters partnerships between recipients and CooperVision scientists to explore new dimensions in visio
- Stoke Therapeutics Presents New In-Vivo Data Demonstrating Dose-Related Target Engagement and OPA1 Protein Upregulation in Retinal Tissue Following Administration of STK-002https://modernod.com/news/stoke-therapeutics-presents-new-in-vivo-data-demonstrating-dose-related-target-engagement-and-opa1-protein-upregulation-in-retinal-tissue-following-administration-of-stk-002/2480831/Stoke Therapeutics announced new preclinical data that demonstrated dose-related target engagement and increases in OPA1 protein levels in retinal tissue of non-human primates (NHPs) following intravitreal (IVT) administration of STK-002. Target engagement and OPA1 protein increases were sus